Use: Labeled indications
- Adapalene and Benzoyl Peroxide gel is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Adapalene and Benzoyl Peroxide gel is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. Adapalene and Benzoyl Peroxide gel, is a combination of adapalene, a retinoid, and benzoyl peroxide and is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older. (1)
Contraindications
4 CONTRAINDICATIONS Adapalene and Benzoyl Peroxide gel is contraindicated in patients with a history of hypersensitivity reactions to benzoyl peroxide or any components of the formulation in Adapalene and Benzoyl Peroxide gel. Adapalene and Benzoyl Peroxide gel is contraindicated in patients with a history of hypersensitivity reactions to benzoyl peroxide or any components of the formulation in Adapalene and Benzoyl Peroxide gel. (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION For topical use only. Adapalene and Benzoyl Peroxide gel is not for oral, ophthalmic, or intravaginal use. Apply a thin layer of Adapalene and Benzoyl Peroxide gel to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek).
Wash hands after application as Adapalene and Benzoyl Peroxide gel may bleach hair or colored fabrics. Avoid the eyes, lips and mucous membranes. For topical use only Adapalene and Benzoyl Peroxide gel is not for oral, ophthalmic or intravaginal use. (2) Apply a thin layer of Adapalene and Benzoyl Peroxide gel to affected areas of the face and/or trunk once daily after washing.
(2) Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). (2) Avoid the eyes, lips, and mucous membranes. (2)
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of Adapalene and Benzoyl Peroxide gel in pediatric patients under the age of 12 have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of Adapalene and Benzoyl Peroxide gel did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects.
Dosage forms
Philippines
- Per gram topical gel: 1 mg/25 mg, 3 mg/25 mg
- Gel: 1 mg/25 mg
- Per gram gel: 1 mg/25 mg
Registered products in the Philippines
6 products registered with the Food and Drug Administration (FDA) Philippines list Adapalene + Benzoyl peroxide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products6
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AC CureAdapalene + Benzoyl Peroxide | 1 mg/25 mg (0.1% / 2.5% w/w) GelPE Tube with white PP cap x 15 g (Box of 1's) | Rx | Dongkoo Bio & Pharma Co., Ltd.Korea | Bestco. Pharma International Corporation | DRP-15747 | Sep 9, 2029 | |
EpiduoAdapalene + Benzoyl Peroxide | 1 mg/25 mg per gram (0.1%/ 2.5% w/w) GelWhite High Density Polyethylene (HDPE) tube with propylene closure (PP) x 5g (as physician's sample) and 15g (Box of 1's) | Rx | Laboratories GaldermaFrance | Importer: Galderma Philippines, Inc. | DR-XY36960 | Nov 10, 2027 | |
EpiduoAdapalene + Benzoyl Peroxide | 1 mg/25 mg per gram (0.1%/2.5% w/w) Topical GelWhite Round Airless Polypropylene (PP) Bottle fitted with a HDPE) and LDPE plunger and stoppered with LDPE and PP pump x 15g, 30g, and 60g (Box of 1's) | Rx | Laboratories GaldermaFrance | Importer: Galderma Philippines, Inc. | DR-XY45741 | Jan 17, 2027 | |
Epiduo ForteAdapalene + Benzoyl Peroxide | 3 mg/25 mg (0.3% w/w/ 2.5% w/w) per gram Topical Gel5 g, 30 g, and 45 g White airless pump system composed mainly of a Polypropylene (PP)/ High- Density Polyethylene (HDPE) bottle and a PP pump/overcap (Box of 1's) | Rx | G Production Inc.Canada | Galderma Philippines, Inc. | DR-XY46058 | Oct 4, 2027 | |
Epiduo ForteAdapalene + Benzoyl Peroxide | 3 mg/25 mg (0.3% w/w/ 2.5% w/w) per gram Topical Gel2g and 5g High Density Polyethylene (HDPE) Tube with Polypropylene (PP) caps (Box of 1's) | Rx | G Production Inc.Canada | Galderma Philippines, Inc. | DR-XY46059 | Oct 4, 2027 | |
Epiduo ForteAdapalene + Benzoyl Peroxide | 3 mg/25 mg per gram (0.3%/2.5% w/w) Topical GelMultidose container with airless pump system designed with a bottle constituted from Polypropylene (PP) and high-density polyethylene (HDPE), fitted with a pump from PP and VLDPE, and a PP cap x 15 g (box of 1's) | Rx | Laboratories GaldermaFrance | Importer: Galderma Philippines, Inc. | DR-XY49199 | Oct 22, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Each gram of Adapalene and Benzoyl Peroxide gel topical gel contains 3 mg (0.3%) adapalene and 25 mg (2.5%) benzoyl peroxide in a white to very pale yellow, opaque gel. Adapalene and Benzoyl Peroxide gel is available in pumps containing 45 g. Topical Gel, 0.3%/2.5%. (3)
Warnings/Precautions
- Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with the use of benzoyl peroxide products. (5.1)
- Photosensitivity: Avoid exposure to sunlight and sunlamps. Wear broad spectrum sunscreen and protective clothing when sun exposure cannot be avoided. (5.2)
- Skin Irritation: Erythema, scaling, dryness, stinging/burning, irritant and allergic contact dermatitis may occur with use of Adapalene and Benzoyl Peroxide gel and may necessitate discontinuation. (5.3)
5.1 Hypersensitivity
5.1 Hypersensitivity Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported with the use of benzoyl peroxide products. If a serious hypersensitivity reaction occurs, discontinue Adapalene and Benzoyl Peroxide gel immediately and initiate appropriate therapy..
5.2 Photosensitivity
5.2 Photosensitivity Avoid exposure to sunlight, including sunlamps, during the use of Adapalene and Benzoyl Peroxide gel. Patients with high levels of sun exposure and those with inherent sensitivity to sun should exercise particular caution. Use of broad spectrum sunscreen products and protective apparel (e.g., hat) are recommended when exposure cannot be avoided.
Weather extremes, such as wind or cold, may be irritating to patients under treatment with Adapalene and Benzoyl Peroxide gel.
5.3 Skin Irritation/Contact Dermatitis
5.3 Skin Irritation/Contact Dermatitis Erythema, scaling, dryness, and stinging/burning may be experienced with use of Adapalene and Benzoyl Peroxide gel. These are most likely to occur during the first four weeks of treatment, are mostly mild to moderate in intensity, and usually lessen with continued use of the medication.
Irritant and allergic contact dermatitis may occur. Depending upon the severity of these adverse reactions, patients should be instructed to use a moisturizer, reduce the frequency of the application of Adapalene and Benzoyl Peroxide gel, or discontinue use. The product should not be applied to cuts, abrasions, eczematous or sunburned skin.
As with other retinoids, use of “waxing” as a depilatory method should be avoided on skin treated with Adapalene and Benzoyl Peroxide gel. Avoid concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have strong skin-drying effect and products with high concentrations of alcohol, astringents, spices or limes).
Adverse reactions
Most commonly reported adverse reactions (≥1%) in patients treated with Adapalene and Benzoyl Peroxide gel were skin irritation, eczema, atopic dermatitis, and skin burning sensation. (6) To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience The following adverse reactions are discussed in greater detail elsewhere in the labeling: Hypersensitivity [see Warnings and Precautions (5.1)] Skin Irritation/Contact Dermatitis [see Warnings and Precautions (5.3)] Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. During the randomized, double-blind, vehicle- and active-controlled clinical trial, 217 subjects were exposed to Adapalene and Benzoyl Peroxide gel.
A total of 197 subjects with acne vulgaris, 12 years and older, were treated once daily for 12 weeks. Adverse reactions reported within 12 weeks of treatment in at least 1% of subjects treated with Adapalene and Benzoyl Peroxide gel and for which the rate with Adapalene and Benzoyl Peroxide gel exceeded the rate for the vehicle are presented in Table 1: Table 1.
Adverse Reactions Occurring in ≥ 1% of Subjects with Acne Vulgaris in a 12-week Clinical Trial Adapalene and Benzoyl Peroxide Gel 0.3%/2.5% (N=217) Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% (N=217) Vehicle Gel (N=69) Skin irritation 4% <1% 0% Eczema 1% 0% 0% Dermatitis atopic 1% 0% 0% Skin burning sensation 1% 0% 0% Local tolerability evaluations presented in Table 2, were conducted at each trial visit in the clinical trial by assessment of erythema, scaling, dryness, and stinging/burning, which peaked at Week 1 of therapy and decreased thereafter. Table 2.
Incidence of Local Cutaneous Irritation in 12-week Clinical Trial in Subjects with Acne Vulgaris Maximum Severity During Treatment End of Treatment Severity (Final Score) Moderate Severe Moderate Severe Adapalene and Benzoyl Peroxide Gel 0.3%/2.5% (N=213) Erythema 20% 1% 4% <1% Scaling 17% 1% 1% <1% Dryness 15% 2% 3% <1% Stinging/Burning 19% 6% 1% 1% Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% (N=212) Erythema 15% 1% 2% <1% Scaling 12% <1% 2% 0% Dryness 13% 1% 2% 0% Stinging/Burning 14% 9% 3% 0% Vehicle Gel (N=68) Erythema 6% 1% 1% 0% Scaling 6% 0% 1% 0% Dryness 4% 1% 1% 0% Stinging/Burning 3% 1% 0% 0%
6.2 Post-Marketing Experience
6.2 Post-Marketing Experience The following adverse reactions have been identified during postapproval use of Adapalene and Benzoyl Peroxide gel. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and subcutaneous tissue disorders: sunburn, blister (including vesicles and bullae), pruritus, hyperpigmentation and hypopigmentation.
Adverse reaction frequency tables (US label) US FDA label
| Adapalene and Benzoyl Peroxide Gel 0.3%/2.5% (N=217) | Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% (N=217) | Vehicle Gel (N=69) | |
| Skin irritation | 4% | <1% | 0% |
| Eczema | 1% | 0% | 0% |
| Dermatitis atopic | 1% | 0% | 0% |
| Skin burning sensation | 1% | 0% | 0% |
| Maximum Severity During Treatment | End of Treatment Severity (Final Score) | |||
| Moderate | Severe | Moderate | Severe | |
| Adapalene and Benzoyl Peroxide Gel 0.3%/2.5% (N=213) | ||||
| Erythema | 20% | 1% | 4% | <1% |
| Scaling | 17% | 1% | 1% | <1% |
| Dryness | 15% | 2% | 3% | <1% |
| Stinging/Burning | 19% | 6% | 1% | 1% |
| Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% (N=212) | ||||
| Erythema | 15% | 1% | 2% | <1% |
| Scaling | 12% | <1% | 2% | 0% |
| Dryness | 13% | 1% | 2% | 0% |
| Stinging/Burning | 14% | 9% | 3% | 0% |
| Vehicle Gel (N=68) | ||||
| Erythema | 6% | 1% | 1% | 0% |
| Scaling | 6% | 0% | 1% | 0% |
| Dryness | 4% | 1% | 1% | 0% |
| Stinging/Burning | 3% | 1% | 0% | 0% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available pharmacovigilance data with Adapalene and Benzoyl Peroxide gel use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with the combination gel.
Adapalene gel, 0.3% Available data from clinical trials with adapalene gel 0.3% use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of adapalene to pregnant rats and rabbits during organogenesis at dose exposures 41 and 81 times, respectively, the human exposure at the maximum recommended human dose (MRHD) of 2g resulted in fetal skeletal and visceral malformations (see Data).
Benzoyl peroxide gel, 2.5% The systemic exposure of benzoyl peroxide is unknown. Based on published literature, benzoyl peroxide is rapidly metabolized to benzoic acid (an endogenous substance), which is eliminated in the urine. Hence, maternal use is not expected to result in fetal exposure of the drug. The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data No malformations were observed in rats treated with oral adapalene doses of 0.15 to 5.0 mg/kg/day, up to 8 times the MRHD of 2 grams of Adapalene and Benzoyl Peroxide gel based on a mg/m 2 comparison.
However, malformations were observed in rats and rabbits when treated with oral doses of ≥ 25 mg/kg/day adapalene (41 and 81 times the MRHD, respectively, based on a mg/m 2 comparison). Findings included cleft palate, microphthalmia, encephalocele, and skeletal abnormalities in rats and umbilical hernia, exophthalmos, and kidney and skeletal abnormalities in rabbits.
Dermal adapalene embryofetal development studies in rats and rabbits at doses up to 6.0 mg/kg/day (9.7 and 19.5 times the MRHD, respectively, based on a mg/m 2 comparison) exhibited no fetotoxicity and only minimal increases in skeletal variations (supernumerary ribs in both species and delayed ossification in rabbits).
Mechanism of action
12.1 Mechanism of Action Adapalene Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown. Benzoyl peroxide Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Pharmacodynamics of Adapalene and Benzoyl Peroxide gel is unknown.
Pharmacokinetics
Excretion of adapalene appears to be primarily by the biliary route.
Benzoyl peroxide is absorbed by the skin where it is converted to benzoic acid and eliminated in the urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics A pharmacokinetic trial was conducted in 26 adult and adolescent subjects (12 to 33 years of age) with severe acne vulgaris who were treated with once-daily applications during a 4-week period with, on average, 2.3 grams/day (range 1.6-3.1 grams/day) of Adapalene and Benzoyl Peroxide gel applied as a thin layer to the face, shoulders, upper chest, and upper back. After a 4-week treatment, 16 subjects (62%) had quantifiable adapalene plasma concentrations above the limit of quantification of 0.1 ng/mL, with a mean C max of 0.16 ± 0.08 ng/mL and a mean AUC 0-24hr of 2.49 ± 1.21 ng.h/mL.
The most exposed subject had adapalene C max and AUC 0-24hr of 0.35 ng/mL and 6.41 ng.h/mL, respectively. Excretion of adapalene appears to be primarily by the biliary route. Benzoyl peroxide is absorbed by the skin where it is converted to benzoic acid and eliminated in the urine. Drug Interactions No formal drug-drug interaction studies were conducted with Adapalene and Benzoyl Peroxide gel.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. adapalene and benzoyl peroxide · Mayne Pharma Inc. [US FDA-approved label, version 4, August 31, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56541736-c70e-4fcd-9614-6cfdc5044136
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .